728 results on '"Santoro, Cristina"'
Search Results
2. Venous thromboembolism secondary prophylaxis in elderly people (over 75-year-old) with low-dose direct oral anticoagulants: single-center Italian experience
3. More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
4. Management of pregnancy and delivery in congenital fibrinogen disorders: communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen
5. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
6. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
7. Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline
8. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
9. Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies
10. Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients
11. Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
12. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
13. Venous thromboembolism secondary prophylaxis in elderly people (over 75-yearold) with low-dose direct oral anticoagulants: single-center Italian experience.
14. F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
15. Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement
16. Fostamatinib combined with TPO‐RAs or steroids as a bridge to monotherapy or as time‐limited continuous treatment in relapsed chronic ITP: A single‐centre case series
17. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
18. Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia
19. Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort
20. Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice
21. Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.
22. The factor VIII treatment history of non‐severe hemophilia A
23. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
24. Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
25. Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years
26. Effect of statin intake on FVIII levels and bleeding outcomes in hypercholesterolemic patients with hemophilia A
27. Secondary prophylaxis of venous thromboembolism (VTE) with low dose apixaban or rivaroxaban: results from a patient population with more than 2 years of median follow-up
28. PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count
29. More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study
30. Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study.
31. The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art.
32. The psychosocial impact of haemophilia from patients’ and caregivers’ point of view: The results of an Italian survey
33. Personalized Prophylaxis with myPKFiTCE: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients
34. Addressing some challenges of congenital fibrinogen disorders in 2023 and beyond
35. S219: PREDICTING THROMBOTIC RISK IN PATIENTS WITH HODGKIN LYMPHOMA: A MULTICENTRIC STUDY OF THROLY AND KHORANA RISK SCORES
36. PB2611: EVANS SYNDROME: DISEASE AWARENESS AND CLINICAL MANAGEMENT IN A NATION-WIDE ITALIAN SURVEY
37. P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
38. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia
39. The psychosocial impact of haemophilia from patients' and caregivers' point of view: The results of an Italian survey.
40. Personalized Prophylaxis with myPKFiT CE : A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients.
41. Severe maternal thrombocytopenia and prenatal invasive procedures: still a grey zone
42. Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres
43. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms
44. Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: a single-center experience
45. Very high risk of intracranial hemorrhage and severe outcomes in adult patients with mild hemophilia: Sub-analysis of the EMO.REC Registry
46. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation
47. Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study
48. IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
49. Efficacy and safety in patients with haemophilia A switching to octocog alfa ( BAY 81–8973): Final results of the global real‐world study, TAURUS
50. Increased von Willebrand Factor Platelet-Binding Capacity Is Related to Poor Prognosis in COVID-19 Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.